ICU Medical (NASDAQ: ICUI) has successfully acquired Smiths Medical from Smiths Group (LSE: SMIN.L), enhancing its position in the infusion therapy market. The combined revenue is projected at approximately $2.5 billion. This acquisition aims to create a scalable US-based competitor, improving supply chain stability and allowing for growth aligned with evolving clinical care models. ICU Medical plans to announce its complete FY 2022 guidance during its Q4 earnings call in late February.
Smiths Detection has secured a contract from the U.S. Department of Homeland Security (DHS) to supply 110 radiation portal monitors (RPM) for enhanced security at land border crossings. This contract, extending their partnership since 2019, underscores the company's commitment to providing robust radiation detection solutions. The RPMs are designed for continuous operation, ensuring effective screening of vehicles and cargo. Deployment is scheduled between December 2021 and May 2023, demonstrating Smiths Detection's dedication to public safety and security technologies.
Warren Mino, Managing Director of Biotechnology for Smiths Detection, urged for increased federal investment in biodetection programs to combat biological threats. Speaking at The Bipartisan Commission on Biodefense, Mino emphasized the need for multi-agency cooperation, technology development, and funding to enhance U.S. biodefense efforts. He cited the COVID-19 pandemic as a critical example of the necessity for proactive measures and advanced detection technologies. Mino's recommendations align with a report from the Commission advocating for federal mandates to protect critical infrastructure against biothreats.
Smiths Detection has secured a contract with Japan Customs to install two high-performance HCVS cargo inspection systems at Kobe and Tokyo ports, beginning in April 2022. These systems will enhance cargo screening by reducing the need for manual inspections and providing rapid, reliable results. Japan, being the world's fourth-largest trader, saw a significant increase of over 20% in imports and exports in August 2021, signaling a strong economic recovery. Smiths Detection aims to bolster trade security and efficiency in these essential port environments.
Smiths Detection, a leader in security screening technologies, confirms that its air sampler, BioFlash, can detect multiple SARS-CoV-2 variants, including Alpha and Delta. The company aims to validate detection of the Lambda variant by Autumn. Previously, BioFlash was recognized by the US Army as capable of detecting airborne SARS-CoV-2, aiding universities in COVID-19 mitigation strategies. BioFlash offers rapid, near-real-time detection without the need for laboratory analysis, enhancing pandemic recovery efforts.
Smiths Detection has officially opened a new global technology development centre in Bangalore, India. This facility will focus on developing digital technologies for security sectors, including aviation, defence, and urban security. The centre will house over 100 team members, enhancing collaboration with global sites in Singapore, France, Germany, UK, and USA. The initiative underscores Smiths Detection's commitment to advancing security technology and business growth.